Expert Insights for Health Science Companies
As a global leader in health science M&A, recapitalization, and growth financing strategies, Crosstree has led 150+ transactions for companies at the center of this fast-moving industry.
Positioning Biobanking Assets for Maximum Value
Leveraging the Precision Medicine Opportunity for Biobanks.
September 9, 2021
As precision medicine grows, so, too, does demand for biobanking services. In this white paper, learn how to evaluate biobank platforms and develop growth strategies that leverage the market shift towards precision medicine.Read White Paper
Pharma Services April 2023
Highlights from this edition: Benchmark Research was acquired by a large public CRO Discovery Life Sciences, Inc. announced its acquisition...
Diagnostics and Tools April 2023
Highlights from this edition: Epic Sciences, In. closed a $24mm Series A Financing, led by Domain Associates, L.L.C., Arsenal Capital...
We were impressed with the intensity and thoroughness of Crosstree’s preparation. Their team worked tirelessly on analytics and positioning, ultimately giving us the flexibility to efficiently navigate various strategic options involving our business and each of its two divisions. I wouldn’t think twice about using Crosstree again.
Crosstree did an exceptional job with our process. We benefited greatly from their industry knowledge, expansive network, deal expertise and just plain hard work. Most importantly, their bankers demonstrated sterling integrity and always gave us sound advice that resulted in an excellent outcome, despite numerous twists and turns along the way.
Crosstree’s specific knowledge of our market segment allowed them to precisely target potential buyers. Further, Crosstree guided management to the right “value drivers” for each potential buyer, optimally tuning our various presentations, and ultimately driving enhanced valuations during the auction process.